Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.68 |
| ▸ | CDK2 | P24941 | 4/20 | 0.68 |
| ▸ | BRD4 | O60885 | 11/20 | 0.56 |
| ▸ | JAK2 | O60674 | 6/20 | 0.56 |
| ▸ | JAK1 | P23458 | 3/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.55 |
| ▸ | BRD2 | P25440 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785037 | 0.86 | CDK2 (0.56) | CDK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL4500110 | 0.81 | CDK2 (1.00) | CDK1CDK2KCNH2 | |
| SCHEMBL1781041 | 0.78 | BRD4 (0.63) | BRD4BRDTPTK2AURKAAURKB | |
| SCHEMBL23255773 | 0.73 | WEE1 (0.78) | CDK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL23256489 | 0.73 | WEE1 (0.83) | CDK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL20230430 | 0.71 | BRD4 (1.00) | BRD4JAK2JAK1BRDTBRD2 | |
| SCHEMBL12236309 | 0.70 | CDK1 (0.54) | CDK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL4731427 | 0.70 | PLK1 (0.68) | CDK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL1675880 | 0.70 | PLK1 (0.86) | CDK1CDK2BRD4BRDTPLK1 | |
| SCHEMBL4515808 | 0.70 | BRD4 (0.82) | BRD4BRDTPTK2EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103298814-A | 2-Anilinopurin-8-ones as TTK/MPS1 inhibitors for the treatment of proliferative diseases | ASTRAZENECA AB | 2013-09-11 | — | — | CN | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | CDK1 31/4885CDK2 134/4885BRD4 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.